Skip to main
CRIS
CRIS logo

Curis (CRIS) Stock Forecast & Price Target

Curis (CRIS) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Curis Inc is positioned for positive growth with the anticipated launch of emavusertib, forecasted to generate revenues of $76.3 million in 2028 for acute myeloid leukemia (AML) and $15.6 million for non-Hodgkin’s lymphoma (NHL) that same year, with substantial growth expected through 2029. The company has demonstrated improved financial performance with third-quarter 2024 revenues slightly exceeding estimates and an upward revision of the 2024 EPS forecast, indicating better-than-expected operational efficiency. Furthermore, recent clinical trial data for emavusertib—showing promising results in patients with relapsed or refractory primary CNS lymphoma—highlights its potential efficacy, bolstering confidence in Curis's therapeutic pipeline.

Bears say

Curis Inc. appears to face significant challenges in its financial outlook, primarily due to its limited product pipeline and ongoing development expenses that may outweigh potential revenue opportunities from its oncology therapies. The company has reported consecutive losses, contributing to a concerning cash flow situation that raises questions about its ability to sustain operations without additional funding or successful commercialization of its drugs. Furthermore, competitive pressures in the biotechnology sector and regulatory hurdles for its treatments could further hinder Curis's growth prospects, leading to a pessimistic view on its future financial performance.

Curis (CRIS) has been analyzed by 14 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Curis and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Curis (CRIS) Forecast

Analysts have given Curis (CRIS) a Buy based on their latest research and market trends.

According to 14 analysts, Curis (CRIS) has a Buy consensus rating as of Jul 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Curis (CRIS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.